I think that is a reasonable estimate especially if you are counting Car-T. There are so many doors that open with the BLA for Lenz. Company has mentioned National Stockpile and Non-Covid ARDS in previous Investor Calls. We are literally Weeks to a Month away from a Phase III EUA that will lead to a BLA in early 2021 for Lenzilumab and becoming the S.O.C. in Covid, and opening doors to so many other applications. There are really big things on tap here.